Junius Falcon
:
Buy when back to 720 or even 650. EPS up 70% YoY by 2025, will end up P/E 30+y, but only little growth in 2026, so it would go sideway in mid term. LLY is diversified drugs, it is safer. NVO needs new drugs than weight loss. If they get out competed in that they are done. Its current EPS growth does support its current P/E
MonkeyGee
:
my target is much lower. but we are in the same direction. LLY shouldn't be anywhere at this price. makes no sense that PFE, which is a stronger company valued at much less than LLY.
KeithNash
:
this is a great stock. Right now, it's getting beaten down, but they are market leader in their field closely, followed by Eli lilly. I see a lot of upside in the long run
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Junius Falcon : Buy when back to 720 or even 650. EPS up 70% YoY by 2025, will end up P/E 30+y, but only little growth in 2026, so it would go sideway in mid term.
LLY is diversified drugs, it is safer. NVO needs new drugs than weight loss. If they get out competed in that they are done. Its current EPS growth does support its current P/E